Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.


NDAQ:ARWR - Post by User

Arrowhead Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(267)
•••
Post by whytestockson Nov 27, 2024 12:30pm
14 Views
Post# 36333827

Buy Recommendation Issued On ARWR By Chardan Capital

Buy Recommendation Issued On ARWR By Chardan Capital
NEWS: $ARWR Buy Recommendation Issued On ARWR By Chardan Capital2024-11-27 11:15:03 ET Chardan Capital analyst issues BUY recommendation for ARWR on November 27, 2024 12:14PM ET. The previous analyst recommendation was Buy. ARWR was trading at $24.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...ARWR - Buy Recommendation Issued On ARWR By Chardan Capital
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities